# ANTIVIRAL MECHANISMS OF 2-5A-DEPENDENT RNASE L > **NIH NIH R01** · CLEVELAND CLINIC LERNER COM-CWRU · 2021 · $402,500 ## Abstract The 2',5'-oligoadenylate (2-5A) synthetase (OAS)-RNase L system is a robust interferon (IFN)-inducible antiviral pathway that contributes to the survival of higher vertebrates against both RNA and DNA viruses. Accordingly, viruses have acquired and evolved a multitude of mechanisms to antagonize OAS-RNase L. During the past 5 years, we established roles for RNase L in IFN signaling, inflammasome activation and autophagy. Yet there remains much to be learned about how RNase L suppresses viral infections, how viruses evade these enzymes, and how the host recovers from RNase L activation. In particular, our knowledge of how RNase L is regulated through its protein kinase-like domain, how RNase L mediates cell death from ADAR1 deficiency, how the RNase L inhibitor (ABCE1 aka RLI) functions, and how RNase L activates the NLRP3 inflammasome is still fragmentary. Therefore, the proposed continuation of this project will systematically investigate the major outstanding questions about this critically important host antiviral pathway. The unifying theme of this application concerns how RNase L function is regulated beyond its activation by 2-5A, in particular through its protein kinase-like (PKL) domain, to control viral infections and inflammation. Our findings lead to the hypothesis that the OAS-RNase L system is an integral part of the host immune system that must be tightly regulated to eliminate viruses while also limiting its harmful pro-inflammatory effects. Our specific aims are: (1) To study the impact of the RNase L PKL domain on cells and viruses we will evaluate recently identified small molecule inhibitors, enhancers and their derivatives on RNase L activity, determine the ability of the small molecules to control viral infections, and investigate effects of the RNase L inhibitors on cell death caused by ADAR1 deficiency. (2) To investigate how the ATP-binding cassette member, ABCE1 (RLI), limits RNase L activity, we will determine precisely how ABCE1 interacts with RNase L to inhibit its activity, establish how the host cells ramps up RNase L activity during viral infections by caspase-mediated cleavage of ABCE1, and determine the ability of ABCE1 to counteract cellular toxicity of double stranded RNA by inhibiting RNase L. (3) To probe the mechanism of NLRP3 inflammasome activation by RNase L, we will identify and characterize RNase L-cleaved viral RNA activators of the NLRP3 inflammasome, determine effects of the small RNA cleavage products on inflammasome activation, and determine the impact of RNase L inhibitor drugs on viral mediated inflammation in vivo. Viral infections remain a serious threat to human health worldwide. Despite viral countermeasures, the OAS-RNase L system has a major impact against many types of pathogenic viruses. These studies emphasize how central and important it is to regulate RNase L in order to mediate the balance between antiviral activity and cell death. It is believed that a better understanding of the vira... ## Key facts - **NIH application ID:** 10236324 - **Project number:** 5R01AI135922-36 - **Recipient organization:** CLEVELAND CLINIC LERNER COM-CWRU - **Principal Investigator:** Robert H. Silverman - **Activity code:** R01 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2021 - **Award amount:** $402,500 - **Award type:** 5 - **Project period:** 2017-09-25 → 2023-08-31 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10236324 ## Citation > US National Institutes of Health, RePORTER application 10236324, ANTIVIRAL MECHANISMS OF 2-5A-DEPENDENT RNASE L (5R01AI135922-36). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10236324. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*